A comparative deep dive for pharma and biotech IP teams, R&D leads, and institutional investors navigating the two most consequential […]
The Economic Imperative of Time In the pharmaceutical sector, time is a tangible asset with a valuation that often exceeds
1. The Pricing Crisis in Numbers The United States spends more per capita on prescription drugs than any other OECD
Precision Medicine Drug Pricing: The Complete IP, Patent, and Market Access Playbook Read Post »
A strategic guide to patent expiry, lifecycle defense, and the economics of generic competition — for executives, investors, and analysts
What Happens When a Drug Patent Expires? Understanding Drug Patent Life Read Post »
1. What a Tentative Approval Actually Means (and What It Doesn’t) A Tentative Approval (TA) letter from the FDA means
FDA Tentative Approval: The Generic Drug Strategist’s Complete Playbook Read Post »
The three largest pharmacy benefit managers, CVS Caremark, Express Scripts (now Evernorth, the health services subsidiary of Cigna), and OptumRx
Every year, dozens of brand-name drugs approach the end of their patent life with billions in annual revenue at stake.
Tentative Drug Approvals: The Definitive Generic Entry Forecasting Playbook Read Post »
How the incentive architecture behind pharmaceutical R&D shapes pipeline decisions, drug pricing, access policy, and $2 trillion in annual investment,
Drug Patents vs. Prize Models: The Complete IP Strategy Guide for Pharma Innovation Read Post »
Every year, the pharmaceutical industry discards hundreds of compounds with known safety profiles, established pharmacokinetics, and years of preclinical data.
Drug Repositioning: The Complete IP, Regulatory, and Investment Playbook Read Post »
Sign in or create a free account to read this DrugPatentWatch article
